Blackwell Kimberly
Known title: DirectorCIK: 0001816465
Blackwell Kimberly's purchase track record
Blackwell Kimberly has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/13/2023 | ZNTL | $51K | +12.1% | +14.5% | +18.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZNTL | ▼ Sell | Tax Withholding | 20,655 | $241K | 2/1/2024 | View on chart |
| ZNTL | ▲ Buy | Grant | 250,000 | $0 | 2/1/2024 | View on chart |
| ZNTL | ▲ Buy | Open Market | 5,000 | $51K | 11/13/2023 | View on chart |
| ZNTL | ▲ Buy | Grant | 244,800 | $0 | 2/1/2023 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 1,000 | $48K | 1/3/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,000 | $84K | 1/3/2022 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 1,000 | $48K | 12/1/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,000 | $82K | 12/1/2021 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 1,000 | $48K | 11/1/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,000 | $80K | 11/1/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,000 | $78K | 10/25/2021 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 1,000 | $48K | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.